Results 61 to 70 of about 5,403 (175)

Nanosensitizer for Cancer Radioimmunotherapy via Anti‐IL‐35 Blockade Boosted Innate Immunity Activation

Advanced Science
The cGAS‐STING signaling pathway has emerged as a promising target for cancer immunotherapy. However, STING agonists have a dual‐edged nature. Although they enhance antitumor T cell activity, STING agonists also elicit protumorigenic effects by promoting
Yinfei Zheng, Shuting Zheng, Yushu Liao, Zede Wu, Chenxi He, Qiuyu Li, Honglei Hu, Zheyu Shen, Yikai Xu, Chenggong Yan, Bingxia Zhao, Meirong Hou   +11 more
doaj   +1 more source

Evaluation of novel highly specific antibodies to cancer testis antigen Centrin‐1 for radioimmunoimaging and radioimmunotherapy of pancreatic cancer

Cancer Medicine, 2019
Background Pancreatic ductal adenocarcinoma (PDAC) accounts for >90% of pancreatic malignancies, and has median survival of 
Rubin Jiao, Kevin J. H. Allen, Mackenzie E. Malo, Muath Helal, Zewei Jiang, Karishma Smart, Susan V. Buhl, David Rickles, Ruth A. Bryan, Ekaterina Dadachova   +9 more
doaj   +1 more source

Review of (90)Y-ibritumomab tiuxetan as first-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin’s lymphoma

Cancer Management and Research, 2009
Christos EmmanouilidesDepartment of Medical Oncology, Interbalkan Hospital, Thessaloniki, GreeceAbstract: Several studies have indicated that radioimmunotherapy is an effective and clinically relevant complementary therapeutic approach for patients with ...
Christos Emmanouilides
doaj  

Beta emitters rhenium‐188 and lutetium‐177 are equally effective in radioimmunotherapy of HPV‐positive experimental cervical cancer

Cancer Medicine, 2016
Cervical cancer caused by the infection with the human papillomavirus (HPV) remains the fourth leading killer of women worldwide. Therefore, more efficacious treatments are needed.
Rebecca Phaeton, Zewei Jiang, Ekaterina Revskaya, Darrell R. Fisher, Gary L. Goldberg, Ekaterina Dadachova   +5 more
doaj   +1 more source

Toxicological Studies of 212Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial

Pharmaceuticals, 2015
Faced with the novelty of a 212Pb-labeled monoclonal antibody (mAb) for clinical translation, concerns were expressed by the Food and Drug Administration (FDA) regarding 212Pb prematurely released from the mAb-chelate conjugate.
Diane E. Milenic, Alfredo A. Molinolo, María S. Solivella, Eileen Banaga, Julien Torgue, Sarah Besnainou, Martin W. Brechbiel, Kwamena E. Baidoo   +7 more
doaj   +1 more source

Increased risk of secondary malignancies after autologous transplantation in R/R follicular lymphoma: Long‐term results from FIL‐FLAZ12 Phase III trial

HemaSphere, Volume 10, Issue 8, August 2026.
Rita Tavarozzi, Andrea Evangelista, Manuela Zanni, Chiara Consoli, Alessandra Tucci, Barbara Botto, Silvia Bolis, Pietro Lauzzana, Vittorio Ruggero Zilioli, Benedetta Puccini, Annalisa Arcari, Vincenzo Pavone, Gloria Margiotta‐Casaluci, Monica Tani, Federica Cavallo, Antonio Pinto, Chiara Ghiggi, Domenico Pastore, Paolo Corradini, Andrés José María Ferreri, Angelo Palmas, Caterina Patti, Francesca Re, Fabio Benedetti, Giuseppe Milone, Stefano Luminari, Elsa Pennese, Elisa Bossi, Carola Boccomini, Antonella Anastasia, Chiara Bottelli, Donato Mannina, Samantha Pozzi, Catello Califano, Luca Arcaini, Flavio Falcinelli, Giuseppe Pietrantuono, Ilaria Del Giudice, Sara Usai, Jacopo Olivieri, Filippo Gherlinzoni, Attilio Olivieri, Tommasina Perrone, Fabrizio Pomponi, Giovannino Ciccone, Umberto Vitolo, Marco Ladetto   +46 more
wiley   +1 more source

Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177Lutetium

Pharmaceutics, 2019
Melanoma is a cancer with increasing incidence and there is a need for alternatives to immunotherapy within effective approaches to treatment of metastatic melanoma.
Kevin J. H. Allen, Rubin Jiao, Mackenzie E. Malo, Connor Frank, Darrell R. Fisher, David Rickles, Ekaterina Dadachova   +6 more
doaj   +1 more source

Radioimmunotherapy: a brief overview

Biomedical Imaging and Intervention Journal, 2006
With the advent of biotechnological advances and knowledge of molecular and cellular biology, radioimmunotherapy (RIT) has become a highly promising oncologic therapeutic modality with established clinically efficacy, particularly in non-Hodgkin's lymphomas.
openaire   +2 more sources

Radioimmunotherapy for Colorectal Cancer [PDF]

Clinical Cancer Research, 2005
Monoclonal antibodies, selected for their ability to recognize and bind tumor-specific antigens, are a promising vehicle for systemic antitumor therapy. Radioimmunotherapy utilizes radioisotopes conjugated to monoclonal antibodies to deliver tumoricidal radiation doses.
openaire   +2 more sources

Combination of 131I-anti-endoglin monoclonal antibody and 5-fluorouracil may be a promising combined-modality radioimmunotherapy strategy for the treatment of hepatocellular carcinoma

Biotechnology & Biotechnological Equipment, 2018
The present study aimed to investigate the therapeutic efficacy of combined radioimmunoconjugate 131I endoglin (ENG) and 5-fluorouracil (5-FU) in mouse model with hepatocellular carcinoma (HCC).
Chongling Duan, Yanxiang Li, Weifei Yang, Chao Zhang   +3 more
doaj   +1 more source